The University of Chicago Header Logo

Connection

Mark J. Ratain to Cohort Studies

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Cohort Studies.
Mark J. Ratain
Connection Strength
0.469
Cohort Studies
  1. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.090
  2. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.058
  3. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.053
  4. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
    View in: PubMed
    Score: 0.037
  5. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
    View in: PubMed
    Score: 0.037
  6. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
    View in: PubMed
    Score: 0.026
  7. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32.
    View in: PubMed
    Score: 0.026
  8. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995 Sep; 13(9):2196-207.
    View in: PubMed
    Score: 0.020
  9. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
    View in: PubMed
    Score: 0.019
  10. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.018
  11. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
    View in: PubMed
    Score: 0.016
  12. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991 Nov; 9(11):2021-6.
    View in: PubMed
    Score: 0.015
  13. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46.
    View in: PubMed
    Score: 0.013
  14. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos. 2007 Dec; 35(12):2149-53.
    View in: PubMed
    Score: 0.011
  15. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
    View in: PubMed
    Score: 0.011
  16. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
    View in: PubMed
    Score: 0.006
  17. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
    View in: PubMed
    Score: 0.006
  18. Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma. 1994; 14 Suppl 1:89-93.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.